Clinical trial
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus…
NCT00319332 · GlaxoSmithKline, Industry · Withdrawn
Key facts
| NCT number | NCT00319332 |
|---|---|
| Title | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen |
| Official title | A Multi-center, Randomized, Phase 3 Study of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen for Patients With Relapsed or Transformed Follicular Non-Hodgkin's Lymphoma |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Small Cleaved-Cell, Follicular, Large-Cell, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | Ibritumomab Tiuxetan, Iodine I 131 Tositumomab |
| Enrollment | 0 |
| Start date | Sep 1, 2005 |
| Primary completion | Feb 1, 2021 |
| Completion | Feb 1, 2021 |
| First posted | Apr 27, 2006 |
| Last update posted | Apr 17, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: